Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) has filed an extensive provisional patent application with the U.S. Patent & Trademark Office on a new “Method for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs.” The method, developed by Cannabics Pharmaceuticals, expands the company’s proprietary technology of personalization of cannabinoid medicine. The current invention pertains to a combined method and system for assessing the sensitivity of a variety of cannabinoid-based treatment modalities on patient-derived primary tumor biopsies as well as blood circulating tumor cells (CTC).
In the news release, Dr. Moran Grinberg, Cannabics Pharmaceuticals Vice President of Research and Development, said, “There is a need for a more personalized approach toward drug development and diagnosis that takes into account the diversity of cancer patients, as well as the complex milieu of tumor cells within a single patient.”
To view the full press release, visit http://nnw.fm/t9A6m
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools. For more information on Cannabics Pharmaceuticals Inc. visit http://cannabics.com/
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
